Sangamo Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Sangamo Therapeutics

31/07/2023 12:29

* Sangamo Therapeutics Inc  SGMO.OQ   SGMO.O  is expected
to show
a fall in quarterly revenue when it reports  results on August 2
(estimated). 
    * The Brisbane California California-based  company is
expected to
report  a 49.5% decrease in revenue to $14.832 million from
$29.38 million a year ago, according to the mean estimate from
10 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Sangamo
Therapeutics Inc
is for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $8​, above​ its last closing price of $1.32.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.32       -0.33      0.12      Beat    136.6
 Dec. 31 2023  -0.35       -0.36      -0.32     Beat    11.1
 Sep. 30 2022  -0.34       -0.36      -0.34     Beat    4.3​
 Jun. 30 2022  -0.33       -0.35      -0.29     Beat    17.8
 ​​Mar.        -0.31       -0.31      -0.30     Beat    3.5
 31 2022                                                
 Dec. 31 2021  -0.35       -0.35      -0.26     Beat    24.7​
 Sep. 30 2021  -0.34       -0.34      -0.33     Beat    2.1
 Jun. 30 2021  -0.33       -0.31      -0.33     Missed  -5.5
 This summary was machine generated July 31 at 11:29 GMT.  All
figures in US dollars  unless otherwise stated